Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zinc lactobionate is a topical small molecule salt composed of zinc and lactobionic acid, developed for the treatment of atopic dermatitis (AD). It functions as a pH-modulating agent that restores the skin's natural acidic mantle, which is typically compromised (elevated pH) in AD patients. By lowering the skin surface pH to approximately 4.5, zinc lactobionate inhibits pH-dependent serine proteases, such as chymotrypsin-like protease (KLK7), which are responsible for accelerated desquamation and barrier degradation. Additionally, the acidic environment promotes the activity of enzymes involved in lipid processing, thereby strengthening the epidermal permeability barrier and reducing transepidermal water loss (TEWL). Clinical studies have demonstrated that zinc lactobionate emollient creams significantly improve skin hydration, reduce sensitivity to irritants, and lower SCORAD (Scoring Atopic Dermatitis) indices.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on zinc lactobionate.